---
title: "Pharscin Pharma obtained the drug registration certificate for Crizotinib capsules"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/261847712.md"
description: "Pharscin Pharma has obtained the drug registration certificate for Crizotinib capsules issued by the National Medical Products Administration. This drug was launched in the Chinese market in 2013 and was included in the medical insurance system in 2018, with over ten years of clinical application experience, primarily used for the treatment of patients with advanced non-small cell lung cancer who are ALK-positive and ROS1-positive"
datetime: "2025-10-20T09:43:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261847712.md)
  - [en](https://longbridge.com/en/news/261847712.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261847712.md)
generator: "portal-rs"
---

# Pharscin Pharma obtained the drug registration certificate for Crizotinib capsules

According to the news from Zhitong Finance APP, Pharscin Pharma (002907.SZ) announced that the company has received the "Drug Registration Certificate" for its product Crizotinib Capsules approved and issued by the National Medical Products Administration. Crizotinib Capsules were launched in the Chinese market in 2013, included in medical insurance in 2018, and have accumulated over ten years of clinical application experience. This drug is primarily used in clinical settings for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for anaplastic lymphoma kinase (ALK), as well as patients with advanced non-small cell lung cancer (NSCLC) who are positive for ROS1

### Related Stocks

- [002907.CN](https://longbridge.com/en/quote/002907.CN.md)

## Related News & Research

- [REG - Aberdeen Asian Inc - Director/PDMR Shareholding](https://longbridge.com/en/news/296505605.md)
- [Cocoa Prices Fall on Rising Nigerian Cocoa Exports](https://longbridge.com/en/news/296637826.md)
- [FLU: Profit and EBITDA up on Malta growth and cost cuts, with 2026 guidance raised](https://longbridge.com/en/news/296306424.md)
- [Ximei Resources clarifies tantalum pricing mechanism in Ganfeng Lithium procurement deal](https://longbridge.com/en/news/296362749.md)
- [Innventure directors force management, board to forfeit Accelsius earnout shares tied to DarkNX order](https://longbridge.com/en/news/296352522.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**